Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Plant Biotechnol J. 2010 Oct;8(8):845-61. doi: 10.1111/j.1467-7652.2010.00550.x. Epub 2010 Aug 23.

Review article: commercialization of whole-plant systems for biomanufacturing of protein products: evolution and prospects.

Author information

  • Kentucky Tobacco Research and Development Center, and Department of Plant and Soil Sciences, University of Kentucky, Lexington, KY, USA. mdavies@uky.edu

Abstract

Technology for enabling plants to biomanufacture nonnative proteins in commercially significant quantities has been available for just over 20 years. During that time, the agricultural world has witnessed rapid commercialization and widespread adoption of transgenic crops enhanced for agronomic performance (herbicide-tolerance, insect-resistance), while plant-made pharmaceuticals (PMPs) and plant-made industrial products (PMIPs) have been limited to experimental and small-scale commercial production. This difference in the rate of commercial implementation likely reflects the very different business-development challenges associated with 'product' technologies compared with 'enabling' ('platform') technologies. However, considerable progress has been made in advancing and refining plant-based production of proteins, both technologically and in regard to identifying optimal business prospects. This review summarizes these developments, contrasting today's technologies and prospective applications with those of the industry's formative years, and suggesting how the PM(I)P industry's evolution has generated a very positive outlook for the 'plant-made' paradigm.

© 2010 The Author. Plant Biotechnology Journal © 2010 Society for Experimental Biology and Blackwell Publishing Ltd.

PMID:
20731788
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk